Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice
- PMID: 15730862
- DOI: 10.1016/j.exphem.2004.12.003
Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice
Abstract
Objective: The present study was designed to investigate the influence of the administration sequence of busulphan (Bu) and cyclophosphamide (Cy) during conditioning regimen on myeloablative and immunosuppressive effects and on engraftment.
Methods: Female Balb/C mice were treated with either Bu-Cy or Cy-Bu (assigned order of administration). Bu was administered as 8.75 mg/kg/day x 4 and Cy as 100 mg/kg/day x 2. The control consisted of untreated animals. Bone marrow and spleen were harvested during the conditioning regimen and for up to 19 days after treatment. Colony-forming unit granulocyte macrophage assay was performed on marrow cells. Immunological analyses were performed using spleen cells. Liver status was determined using aspartate amino transferase (AST), alanine amino transferase (ALT), and bilirubin. Animals assigned for engraftment study were conditioned as above and transplanted using sca-1 cells from male Balb/C donors. Engraftment was followed using fluorescence in situ hybridization up to 30 days posttransplantation.
Results: No significant difference in myeloablative effect was observed between treatments. Immunosuppressive activity expressed as CD3+/CD19+ and CD4+/CD8+ was also similar. Levels of cytokines interleukin 2, tumor necrosis factor alpha, and interferon gamma at the end of the conditioning regimen were lower in the Cy-Bu group, while liver enzymes were higher after the Bu-Cy regimen. Engraftment in bone marrow was reached faster within the first 20 days after conditioning with Cy-Bu compared to Bu-Cy. However, no difference in chimerism was observed at 30 days.
Conclusion: Cy-Bu treatment resulted in lower levels of cytokines, faster bone marrow engraftment, and lower values of liver enzymes compared to Bu-Cy regimen, which may benefit stem cell transplantation outcomes.
Similar articles
-
The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model.Bone Marrow Transplant. 2008 May;41(10):895-904. doi: 10.1038/sj.bmt.1705996. Epub 2008 Jan 28. Bone Marrow Transplant. 2008. PMID: 18223695
-
Myeloablative and immunosuppressive properties of treosulfan in mice.Exp Hematol. 2006 Jan;34(1):115-21. doi: 10.1016/j.exphem.2005.09.015. Exp Hematol. 2006. PMID: 16413398
-
Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.Transplant Proc. 2005 Dec;37(10):4477-81. doi: 10.1016/j.transproceed.2005.10.014. Transplant Proc. 2005. PMID: 16387149
-
Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review.
-
The development of busulfan/cyclophosphamide preparative regimens.Semin Oncol. 1993 Aug;20(4 Suppl 4):12-6; quiz 17. Semin Oncol. 1993. PMID: 8342070 Review.
Cited by
-
Addition of romiplostim to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels.Blood Adv. 2022 Aug 9;6(15):4485-4489. doi: 10.1182/bloodadvances.2022007566. Blood Adv. 2022. PMID: 35736667 Free PMC article.
-
Evaluation of Reversed Administration Order of Busulfan (BU) and Cyclophosphamide (CY) as Conditioning on Liver Toxicity in Allogenic Hematopoietic Stem Cell Transplantation (ALL-HSCT).Int J Hematol Oncol Stem Cell Res. 2020 Jul 1;14(3):171-176. doi: 10.18502/ijhoscr.v14i3.3725. Int J Hematol Oncol Stem Cell Res. 2020. PMID: 33024523 Free PMC article.
-
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.Ann Hematol. 2021 Jan;100(1):209-216. doi: 10.1007/s00277-020-04312-y. Epub 2020 Oct 23. Ann Hematol. 2021. PMID: 33098041 Free PMC article. Clinical Trial.
-
Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.Biol Blood Marrow Transplant. 2008 May;14(5):591-4. doi: 10.1016/j.bbmt.2008.02.016. Biol Blood Marrow Transplant. 2008. PMID: 18410902 Free PMC article. Clinical Trial.
-
Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment.Mol Ther. 2018 May 2;26(5):1181-1197. doi: 10.1016/j.ymthe.2018.03.003. Epub 2018 Mar 10. Mol Ther. 2018. PMID: 29622475 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials